DarioHealth Corp. (DRIO) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. DarioHealth Corp. is a global digital therapeutics (DTx) company providing personalized, evidence-based interventions for chronic conditions (diabetes, hypertension, weight management) and behavioral health. The company operates as a single reporting segment with significant operations in Israel and the U.S. As of May 9, 2025, there were 43,949,424 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenues | $6,752 | $5,758 |
| Gross Profit | $3,882 | $2,432 |
| Gross Margin | 57.5% | 42.2% |
| Operating Loss | $(9,409) | $(17,855) |
| Net Loss | $(9,227) | $(7,175) |
| Net Loss Attributable to Common Shareholders | $(14,066) | $(9,209) |
| Diluted Loss Per Share | $(0.14) | $(0.20) |
| Cash and Cash Equivalents (End of Period) | $27,854 | $34,367 |
| Net Cash Used in Operating Activities | $(6,673) | $(13,110) |
| Total Debt (Current + Non-Current) | $29,194 | $28,923 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 17.3% year-over-year, driven primarily by growth in the commercial B2B2C channel ($4,737 vs. $3,470 in Q1 2024).
- Margin Expansion: Gross margin improved significantly to 57.5% from 42.2%, attributed to higher commercial revenue mix and reduced amortization of acquired technology.
- Expense Reduction: Operating expenses decreased 34.5% to $13.29 million. Notable reductions include R&D (-38.2%), Sales & Marketing (-15%), and General & Administrative (-50.9%), largely due to lower stock-based compensation and payroll costs.
- Financial Income Volatility: Net loss increased despite lower operating expenses due to a decrease in financial income. Q1 2024 included significant revaluation gains on pre-funded warrants ($9.18 million) which were not replicated in Q1 2025.
- Liquidity: Cash burn from operations improved by 49.4% compared to the prior year.
Guidance, Outlook, and Risks
Recent Developments & Financing:
- Debt Refinancing: On April 30, 2025 (subsequent to period end), the company refinanced its existing facility with a new $50 million credit agreement ($32.5 million drawn at closing, $17.5 million available). The new facility matures in April 2030.
- Equity Conversions: On April 28, 2025, stockholders approved the conversion of Series D preferred stock into approximately 33.9 million shares of common stock.
- Commercial Wins: Signed 14 new clients in Q1 2025, including a major U.S. healthcare institution and a national benefit plan administrator.
Risks and Contingencies:
- Nasdaq Compliance: The company received an extension until September 15, 2025, to regain compliance with the $1.00 minimum bid price requirement. Failure to comply could result in delisting.
- Geopolitical Risk: Operations in Israel face risks from ongoing regional conflict, including potential employee call-ups for military reserve duty and supply chain disruptions.
- Customer Concentration: One major customer accounted for 19.1% of revenue in Q1 2025.
- Liquidity: Management believes current cash and the new credit facility are sufficient for at least 12 months, but future profitability depends on successful commercialization.
Investor Verification Checklist
- Debt Covenants: Verify the specific revenue and gross margin thresholds required to draw the remaining $17.5 million of the new credit facility.
- Dilution Impact: Assess the impact of the approved conversion of Series D preferred stock (approx. 34 million shares) on future earnings per share.
- Nasdaq Status: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement before the September 2025 deadline.
- Customer Concentration: Review the status of the contract with the major customer representing 19.1% of revenue to assess retention risk.
- Geopolitical Exposure: Evaluate the operational continuity plan for Israeli-based R&D and executive functions amidst regional instability.